Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2014

Marcq Marie, Vallée Audrey, Bizieux Acya, Denis Marc G

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Aged
Share to DNA, Neoplasm
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 24926553
DOI: 10.1097/JTO.0000000000000134
PMCID: PMC4132039

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?PMID 24926553Read ↗

[Several hot issues in the detection of plasma EGFR mutations in advanced non-small-cell lung cancer patients].Semantic proximity Read ↗

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.Semantic proximity Read ↗

The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR‐TKISemantic proximity Read ↗

Plasma EGFR Mutation Detection Associated With Survival Outcomes in Advanced-Stage Lung Cancer.Semantic proximity Read ↗

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistanceSemantic proximity Read ↗

134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC)Semantic proximity Read ↗

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients.Semantic proximity Read ↗

Brief Report: Clinical Outcomes Using Plasma-Based Molecular Profiling to Guide Treatment Decisions in Patients With Advanced NSCLC and Limited Access to Broad Tissue Testing.Semantic proximity Read ↗

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.Semantic proximity Read ↗

Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

Association between clinical characteristics and the diagnostic accuracy of circulating single-molecule amplification and resequencing technology on detection epidermal growth factor receptor mutation status in plasma of lung adenocarcinoma.Semantic proximity Read ↗

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasmaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.